• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Expensify And 2 Other Stocks Under $2 Insiders Are Buying

    6/4/24 7:24:05 AM ET
    $CATX
    $EXFY
    Medical/Dental Instruments
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $CATX alert in real time by email

    The Dow Jones index closed lower by over 100 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

    Expensify

    • The Trade: Expensify, Inc. (NASDAQ:EXFY) Director Timothy L Christen bought a total of 19,162 shares at an average price of $1.61. To acquire these shares, it cost around $30,851.
    • What's Happening: On May 9, Expensify posted downbeat quarterly results.
    • What Expensify Does: Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money.

    Bio Essence

    • The Trade: Bio Essence Corporation (OTC:BIOE) CEO Yin Yan acquired a total of 5,000,000 shares at an average price of $0.50. To acquire these shares, it cost around $2.5 million.
    • What's Happening: The company’s stock jumped around 127% over the past month.
    • What Bio Essence Does: Bio Essence Corp is an herbal health, diet, and nutrition company. The Company’s mission is to provide herbal health, diet, and vitamin nutritional supplements.

    Perspective Therapeutics

    • The Trade: Perspective Therapeutics, Inc. (NASDAQ:CATX) CFO Jonathan Robert Hunt acquired a total of 25,006 shares at an average price of $1.40. The insider spent around $35,007 to buy those shares. The company's Director Robert F Williamson III also bought 55,000 shares of the company.
    • What's Happening: On May 24, Perspective Therapeutics announced the pricing of $80 million underwritten offering of common stock and pre-funded warrants.
    • What Perspective Therapeutics Does: Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body.

    Now Read This: Top 3 Utilities Stocks That May Plunge In Q2

    Get the next $CATX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CATX
    $EXFY

    CompanyDatePrice TargetRatingAnalyst
    Perspective Therapeutics Inc.
    $CATX
    11/24/2025$12.00Buy
    Truist
    Perspective Therapeutics Inc.
    $CATX
    10/10/2025$14.00Buy
    BTIG Research
    Expensify Inc.
    $EXFY
    8/8/2025$3.00 → $2.50Market Perform
    BMO Capital Markets
    Perspective Therapeutics Inc.
    $CATX
    3/13/2025$10.00Buy
    H.C. Wainwright
    Perspective Therapeutics Inc.
    $CATX
    3/7/2025$15.00Sector Outperform
    Scotiabank
    Expensify Inc.
    $EXFY
    11/25/2024Mkt Outperform → Mkt Perform
    JMP Securities
    Perspective Therapeutics Inc.
    $CATX
    11/25/2024$24.00 → $5.00Buy → Neutral
    BofA Securities
    Perspective Therapeutics Inc.
    $CATX
    10/24/2024$20.00Buy
    UBS
    More analyst ratings

    $CATX
    $EXFY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Hunt Jonathan Robert bought $22,295 worth of shares (11,000 units at $2.03), increasing direct ownership by 23% to 59,800 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/17/25 8:01:56 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Director Williamson Robert F Iii bought $19,946 worth of shares (9,498 units at $2.10) (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/14/25 8:00:03 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Director Christen Timothy L bought $57,200 worth of shares (40,000 units at $1.43), increasing direct ownership by 16% to 289,754 units (SEC Form 4)

    4 - Expensify, Inc. (0001476840) (Issuer)

    11/13/25 5:52:23 PM ET
    $EXFY
    Computer Software: Prepackaged Software
    Technology

    $CATX
    $EXFY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Expensify and Xero Enhance Partnership to Support Small Businesses

    The new partnership offers customers Xero for free for six months and six months of Expensify for 50% off. Expensify, Inc. (NASDAQ:EXFY), the easiest way to manage expenses, corporate cards, and travel, today announced an expanded partnership with Xero, a global leader in cloud-based accounting software, to deliver exclusive discounts and joint marketing campaigns that simplify operations for small businesses. The collaboration enhances the relationship between two of the most trusted platforms in spend management and accounting, offering new customers significant savings and increased visibility into industry-leading integration options across both ecosystems. "This partnership is ab

    2/12/26 9:00:00 AM ET
    $EXFY
    Computer Software: Prepackaged Software
    Technology

    Expensify to Announce Q4 and Full Year 2025 Results

    Join Expensify's earnings call on Thursday, February 26th at 2pm PT / 5pm ET. Expensify, Inc. (NASDAQ:EXFY), the easiest way to manage expenses, corporate cards, and travel, today announced that the company's Q4 and full year 2025 financial results will be released after market close on Thursday, February 26th, 2026. Expensify will host a call to discuss its Q4 and full year fiscal 2025 results on Thursday, February 26th, 2026 at 2pm PT / 5pm ET. The link to the call will be available that day on the company's Investor Relations website at investors.expensify.com. Prior to the call, interested parties can visit the website to add the event to their calendars. After the call, the follo

    2/12/26 9:00:00 AM ET
    $EXFY
    Computer Software: Prepackaged Software
    Technology

    Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

    SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced the pricing of an underwritten offering of 39,576,088 shares of its common stock at an offering price of $3.79 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 6,598,046 shares of its common stock at a price of $3.789 per pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $175 million, before deducting underwriting discounts and commissions and other offering expe

    2/2/26 8:35:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    $EXFY
    SEC Filings

    View All

    Perspective Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    2/3/26 4:07:20 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form FWP filed by Perspective Therapeutics Inc.

    FWP - Perspective Therapeutics, Inc. (0000728387) (Subject)

    2/2/26 7:45:25 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    2/2/26 7:44:33 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    $EXFY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Barrett David Michael sold $43,500 worth of shares (30,000 units at $1.45) (SEC Form 4)

    4 - Expensify, Inc. (0001476840) (Issuer)

    2/4/26 6:10:01 PM ET
    $EXFY
    Computer Software: Prepackaged Software
    Technology

    Director Alvarez Divo Carlos Eduardo sold $13,507 worth of shares (8,972 units at $1.51) and disposed of 33,592 shares, decreasing direct ownership by 13% to 285,508 units (SEC Form 4)

    4 - Expensify, Inc. (0001476840) (Issuer)

    1/12/26 6:14:02 PM ET
    $EXFY
    Computer Software: Prepackaged Software
    Technology

    New insider Alvarez Divo Carlos Eduardo claimed ownership of 328,072 shares (SEC Form 3)

    3 - Expensify, Inc. (0001476840) (Issuer)

    1/12/26 4:24:08 PM ET
    $EXFY
    Computer Software: Prepackaged Software
    Technology

    $CATX
    $EXFY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist resumed coverage on Perspective Therapeutics with a new price target

    Truist resumed coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $12.00

    11/24/25 9:17:24 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    BTIG Research initiated coverage on Perspective Therapeutics with a new price target

    BTIG Research initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $14.00

    10/10/25 8:39:44 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    BMO Capital Markets reiterated coverage on Expensify with a new price target

    BMO Capital Markets reiterated coverage of Expensify with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously

    8/8/25 7:50:56 AM ET
    $EXFY
    Computer Software: Prepackaged Software
    Technology

    $CATX
    $EXFY
    Leadership Updates

    Live Leadership Updates

    View All

    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

    SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed

    9/4/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

    SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company's Board of Directors, effective today. Ms. Martinez-Davis currently serves as President of GSK's U.S. Commercial business, a position she has held since September 2019. In that role, she leads a robust and complex business portfolio of products in specialty, respiratory, oncology and vaccines. Prior to GSK, Ms. Martinez-Davis was President of biopharma Latin

    9/3/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

    6/24/25 12:52:00 PM ET
    $AUTL
    $CATX
    $INDP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $CATX
    $EXFY
    Financials

    Live finance-specific insights

    View All

    Expensify to Announce Q4 and Full Year 2025 Results

    Join Expensify's earnings call on Thursday, February 26th at 2pm PT / 5pm ET. Expensify, Inc. (NASDAQ:EXFY), the easiest way to manage expenses, corporate cards, and travel, today announced that the company's Q4 and full year 2025 financial results will be released after market close on Thursday, February 26th, 2026. Expensify will host a call to discuss its Q4 and full year fiscal 2025 results on Thursday, February 26th, 2026 at 2pm PT / 5pm ET. The link to the call will be available that day on the company's Investor Relations website at investors.expensify.com. Prior to the call, interested parties can visit the website to add the event to their calendars. After the call, the follo

    2/12/26 9:00:00 AM ET
    $EXFY
    Computer Software: Prepackaged Software
    Technology

    Expensify Announces Q3 2025 Results

    Total interchange derived from the Expensify Card grew to $5.4 million, an increase of 18% as compared to the same period last year. Expensify, Inc. (NASDAQ:EXFY), the easiest way to manage expenses, corporate cards, and travel, today released a letter to shareholders from Founder and CEO David Barrett alongside results for its quarter ended September 30, 2025. A Message From Our Founder Expensify continues to generate free cash flow, grow interchange (up 18% y/y), and grow travel bookings (up 95% since Q1). We're standing by our FY'25 free cash flow guidance of $19.0 million to $23.0 million, and have announced that Expensify is the Official Travel and Expense partner of the Brooklyn Ne

    11/6/25 4:00:00 PM ET
    $EXFY
    Computer Software: Prepackaged Software
    Technology

    Expensify to Announce Q3 2025 Results

    Join Expensify's earnings call on Thursday, November 6th at 2pm PT / 5pm ET. Expensify, Inc. (NASDAQ:EXFY), the easiest way to manage expenses, corporate cards, and travel, today announced that the company's Q3 2025 financial results will be released after market close on Thursday, November 6th, 2025. Expensify will host a call to discuss its Q3 2025 results on Thursday, November 6th 2025 at 2pm PT / 5pm ET. The link to the call will be available that day on the company's Investor Relations website at investors.expensify.com. Prior to the call, interested parties can visit the website to add the event to their calendars. After the call, the following will be made available at investor

    10/23/25 9:00:00 AM ET
    $EXFY
    Computer Software: Prepackaged Software
    Technology

    $CATX
    $EXFY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Expensify Inc.

    SC 13G/A - Expensify, Inc. (0001476840) (Subject)

    11/20/24 5:30:35 PM ET
    $EXFY
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by Perspective Therapeutics Inc.

    SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/14/24 6:14:40 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

    SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/14/24 4:05:13 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care